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Edited by Varda RotterAbstract Cisplatin is a widely used antineoplastic drug. Major
drawback of cisplatin therapy is its nephrotoxicity. The objective
of this study was to check the eﬀect of tannic acid on cisplatin
induced nephrotoxicity. Post-treatment of tannic acid pre-
vents cisplatin (5 mg/kg) induced nephrotoxicity and decreases
poly(ADP-ribose) polymerase cleavage, phosphorylation of p38
and hypoacetylation of histone H4. In contrast, co-treatment
of tannic acid potentiates the nephrotoxicity. Comparative neph-
rotoxicity studies show that co-treatment of tannic acid with
reduced dose of cisplatin (1.5 mg/kg) developed almost similar
nephrotoxicity. MALDI protein proﬁling of plasma samples pro-
vides indirect evidence that tannic acid co-treatment increases
bioavailability of cisplatin.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cisplatin (CP) remains the drug of choice in many platinum
based chemotherapy regimens. It acts by damaging DNA ow-
ing to platination to form covalent platinum DNA adducts [1].
DNA damage elicits a series of signal transduction cascades,
involving chromatin remodeling, which eventually lead to
DNA repair, cell cycle arrest or apoptosis [2–5]. The therapeu-
tic eﬀects of cisplatin are dose dependent but the chief limit to
its promising eﬃcacy as an antineoplastic drug is its nephro-
toxicity [6,7]. Use of other means to prevent nephrotoxicity
e.g. hydration protocols [8], antioxidant supplementation [9]
have proven to be partially successful due to the repeated dos-
ing schedules of CP. Therapeutic interventions aimed at ame-
liorating renal damage require the use of combinationAbbreviations: CP, cisplatin; PARP, poly(ADP-ribose) polymerase;
PARG, poly(ADP ribose) glycohydrolase; BUN, blood urea nitrogen;
MAPK, mitogen activated protein kinases; ROS, reactive oxygen
species
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doi:10.1016/j.febslet.2007.04.036therapies. This indicts the involvement of reactive oxygen spe-
cies (ROS) generation as a mediator in inﬂicting nephrotoxic
insult in CP therapy. Interaction of cisplatin with CYP2E1 re-
sults in the generation of reactive oxygen metabolites that
causes renal injury and initiates apoptosis. Recent report
shows that cytochrome P450 2E1 null mice provide novel pro-
tection against cisplatin induced nephrotoxicity and apoptosis
[10].
Polyphenolics are known for their potent antioxidant and
free radical scavenging properties. It signiﬁcantly aﬀects the
pathways which are involved in the detoxiﬁcation of chemical
carcinogens particularly those in which CYP2E1 and
NAD(P)H:quinone oxidoreductase (NQO1) are involved
[11]. It is also reported that administration of tannic acid (gal-
lotannin) resulted in a marked decrease in the expression of
hepatic CYP2E1, but there are no reports which address the
relevance of this polyphenol with respect to its role in mediat-
ing or preventing the toxic eﬀects. In addition to tannic acid,
other tannins have been shown to exert various biological
eﬀects ranging from anti-inﬂammatory to anticancer and anti-
viral eﬀects [12–16]. The mechanism underlying the anti-
inﬂammatory eﬀects of tannins include the scavenging of
radicals; antioxidant eﬀect [17,18] and inhibition of the
expression of inﬂammatory mediators, such as some cyto-
kines [12], including nitric oxide synthase, and cylooxgenase-
2[19].
Renal tubular apoptosis has been implicated as a ﬁnal com-
mon pathway in response to a variety of cellular stresses at
intensity below the threshold for necrosis [20,21]. Poly(ADP-
ribose) polymerase (PARP), an enzyme involved in DNA dam-
age and repair. It is also activated in conditions of oxidative
stress caused by depletion of antioxidant enzymes by CP
[22,23]. Poly(ADP-ribose) glycohydrolase (PARG) is another
enzyme that keeps PARP in active state by hydrolytic cleavage
of poly(ADP-ribose) (PAR) [24–26]. Inhibition of PARP can
be obtained by the use of PARP/PARG inhibitors [27]; PARG
inhibitors have shown cytoprotection against various tissue
injuries in vivo as well as in vitro cell systems [28]. Tannic acid,
a PARG inhibitor showed cytoprotection against ischemic
reperfusion injury where oxidative stress is known to play a
key role [29,30].
Novel strategies aimed at minimizing nephrotoxicity while
enhancing its antineoplastic eﬃcacy are incomplete until a
more basic understanding of its toxicity is obtained. The objec-
tive of the present study was to study the eﬀect of tannic acid in
cisplatin induced nephrotoxicity.blished by Elsevier B.V. All rights reserved.
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2.1. Reagents and solutions
cis-Diamminplatinumdichloride (cisplatin, CP) was obtained from
Dabur India Pvt. Ltd. as a gift sample. Tannic acid was obtained from
Merck, Germany. Trypsin was purchased from Promega Corporation
(UK). All the other chemicals were purchased from Sigma (St. Louis,
MO). Cisplatin solution was made freshly in saline (0.9% NaCl). Tan-
nic acid was prepared freshly in phosphate buﬀer of pH 7.4.2.2. Animal treatment and experimental protocol
All the experiments were approved by the Institutional Animal Eth-
ics Committee (IAEC) and complied with the NIH guidelines on han-
dling of experimental animals. Experiments were performed on male
Sprague–Dawley rats in the weight range of 170–190 g which were pro-
cured from the central animal facility of the institute, kept at con-
trolled environmental conditions with room temperature 22 ± 2 C
and 12 h light/dark cycles. Rats were divided at random into diﬀerent
groups, eight animals in each group. In co-treatment group single dose
of tannic acid (10 mg/kg) was administered just after the CP (5 mg/kg)
treatment. In post-treatment group three consecutive doses of tannic
acid (10 mg/kg) were given from next day of CP treatment. Drugs were
administered by intraperitoneal (i.p.) route.
For comparative nephrotoxicity proﬁle, rats were divided randomly
into two groups, received either a single injection of CP (1.5 mg/kg,) or
co-treatment of CP (1.5 mg/kg) with single dose of tannic acid (10 mg/
kg). Rats were weighed prior to injection and four day after CP treat-
ment. Blood samples were collected on ﬁfth day, from the retro orbital
plexus of rats under light ether anesthesia in heparinized centrifuge
tubes and immediately centrifuged at 2300 · g for the separation of
plasma. Plasma was stored at 20 until assayed.2.3. Estimation of plasma creatinine, blood urea nitrogen (BUN) and
plasma albumin
Plasma creatinine concentration was measured by the picric acid col-
orimetric method [31]. A picric acid solution was made by a tenfold
dilution of saturated picric acid with 1% NaOH. Plasma (50 ll) was
added to picric acid–NaOH solution (200 ll) in a micro titer plate.
The samples were allowed to incubate for 15 min before being read
at 490 nm in a micro plate reader. A standard curve was prepared
on the same assay plate to derive the creatinine concentration. BUN
and plasma albumin were determined colorimetrically using commer-
cially available standard kits.2.4. Histopathological procedures
Rats were anesthetized under light ether anesthesia, after surgery cir-
culating blood was removed by cardiac perfusion with 0.1 M PBS (pH
7.4; 20–50 ml). After clearance of circulating blood, 4% paraformalde-
hyde in 0.1 M phosphate buﬀer (pH 7.4) was perfused for another
5 min (100–200 ml of ﬁxative) to ﬁx the tissues. Kidneys were removed
from the animal, decapsulated, sliced transversely, and paraﬃn-
embedded for light microscopic evaluation. Histopathological changes
in kidney structure were assessed in at least 25 randomly selected tissue
sections from each group studied. Sections were stained with Meyer’s
hematoxylin and eosin to examine cell structure. Slides were observed
under Olympus microscope (Model no. BX51).Table 1
Changes in body weight and biochemical parameters by co and post treatm
Treatment groups Change in body w
Vehicle control (0.9% saline) 19 ± 2
Tannic acid (10 mg/kg) control co-treatment 17 ± 1
Tannic acid (10 mg/kg) control post-treatment 9.4 ± 1.3
CP treated (5 mg/kg) (–)11 ± 3***a
CP (5 mg/kg) + tannic acid (10 mg/kg) co-treatment (–)14 ± 2***ab
CP (5 mg/kg) + tannic acid (10 mg/kg) post-treatment (–)8 ± 2.5***a
Biochemical parameters were estimated after 5 days of CP (5 mg/kg) and tan
expressed as means ± S.E.M. (n = 8), ***P < 0.001, **P < 0.01, *P < 0.05, a v2.5. Nuclei isolation and Western blotting
Nuclei were isolated and acid soluble proteins were extracted
according to method described previously [32]. For nuclear protein,
nuclei were suspended in buﬀer (1% NP-40, 10 mM Tris, 10 mMNaCl,
10 mM EDTA, 10 lg/ml aprotinin, 10 lg/ml leupeptin, and 1 mM
phenylmethanesulfonyl ﬂuoride (PMSF)) and its protein concentration
was determined by the method of Lowry et al. [33].
For Western blot analysis, nuclear proteins were transferred onto
PVDF membrane (Bio-Rad) and immunoblot analysis was performed
by using the anti-acetyl histone H4 (rabbit monoclonal 1:5000, Up-
state), anti p38, anti p-p38 (rabbit 1:500, Santa Cruz Biotechnology
Inc.), anti-PARP (rabbit 1:250, Upstate), anti actin (rabbit 1:2500,
Sigma), and HRP-conjugated secondary antibodies (anti-rabbit, Cal-
biochem). Proteins were detected with the enhanced chemilumines-
cence (ECL) system and ECL Hyperﬁlm (Amersham Pharmacia
Biotech).
2.6. MALDI plasma protein proﬁling
For MALDI plasma protein proﬁling, 16 SD rats of weight 170–
190 g were divided into four groups, four animals in each group. In
the ﬁrst group vehicle for CP and tannic acid was administered, in sec-
ond group CP (5 mg/kg) was injected, in the third group co-treatment
of tannic acid (10 mg/kg) with cisplatin (5 mg/kg) was given and the
fourth group was treated with tannic acid (10 mg/kg). Blood samples
were collected and plasma was separated by centrifugation for
10 min at 2300 · g and stored at 20 C until analysis.
After 20 times dilution of plasma, plasma protein was estimated [33].
Then 10 lg proteins from each sample was digested for over night at
37 C with 100 ng of modiﬁed trypsin (Promega Corporation, UK).
For protein mass spectra 1 ll of the digested protein was mixed with
1 ll alpha-cyano hydroxy cinnamic acid solution matrix, dried and
washed twice with 0.1% Triﬂuoroacetic acid. Protein proﬁles were
accumulated from dried-droplet deposits of matrix/peptide mixture
by MALDI-TOF mass spectrometer (Bruker Daltonics ﬂexanalysis),
externally calibrated using peptide standard mix (Bruker Daltonics)
and 200 shots were accumulated to give an acceptable spectrum. For
each digest, triplicate MALDI spots were deposited and analyzed.
Ion signals above a signal-to-noise (S/N) ratios of 10 were considered
for comparison. Peak intensities ratios of treated to control samples
were calculated by averaging the peak intensities followed by t-tests
of the intensity of each individual peaks.2.7. Statistical analysis
Data are expressed as means ± S.E.M. Statistical comparison be-
tween diﬀerent groups were done using one-way analysis of variance
(ANOVA) followed by tukey multiple comparison test, to detect the
diﬀerence between various groups. P value less than 0.05 was consid-
ered to be signiﬁcant.3. Results
3.1. Cisplatin induced changes in body weight
CP induced nephrotoxicity can easily be assessed by de-
crease in body weight, urine out put and water intake. CP
treatment leads to a signiﬁcant decrease in body weight asent of tannic acid on CP induced nephrotoxicity in SD rats
t (g) BUN (mg/dl) Creatinine (mg/dl) Albumin (g/dl)
21 ± 0.79 0.68 ± 0.04 3.67 ± 0.03
20 ± 1.07 0.84 ± 0.08 3.34 ± 0.08
19 ± 0.23 0.79 ± 0.02 2.9 ± 0.04*a
85 ± 11.7***a 2.18 ± 0.24***a 3.27 ± 0.09***a
124 ± 12***ab 4.35 ± 0.21***a 3.08 ± 0.13***a
40 ± 4.18***ab 1.25 ± 0.15**ab 2.8 ± 0.09**ab
nic acid (10 mg/kg) treatment, as described in Section 2. All values are
s vehicle control group, b vs tannic acid group or CP treated group.
Table 2
Comparative nephrotoxicity proﬁling
Treatment groups BUN (mg/dl) Creatinine (mg/dl)
Vehicle control (0.9% saline) 21 ± 0.79 0.68 ± 0.04
Tannic acid control 20 ± 1.07 0.84 ± 0.08
CP treated (5 mg/kg) 85 ± 11.7*** 2.18 ± 0.24***
CP treated (1.5 mg/kg) 28 ± 3.67*** 1.17 ± 0.08***
CP (1.5 mg/kg) + tannic
acid (10 mg/kg)
62 ± 11*** 1.38 ± 0.05***
Changes in biochemical parameters by co-treatment of tannic acid on
cisplatin induced nephrotoxicity in SD rats. Biochemical parameters
were estimated after 5 days of cisplatin (5 mg/kg and 1.5 mg/kg) and
tannic acid (10 mg/kg) treatment, as described in Section 2. All values
are expressed as means ± S.E.M. (n = 5), ***P < 0.001 vs vehicle con-
trol group.
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water intake and urine output of CP treated rats was also ob-Fig. 1. Histopathological changes in kidney after co- and post-treatment of ta
kidney (A) and (B), CP treated kidney (C) and (D), co-treatment of tannic ac
were stained with Mayer’s hematoxylin counterstained with eosin and obser
indicates cells undergoing apoptotic cell death.served suggesting development of nephrotoxicity (data not
shown).3.2. Changes in BUN, creatinine and albumin levels by co- and
post-treatment of tannic acid with cisplatin
CP treated rats developed polyuric acute renal failure as as-
sessed by measuring diﬀerent biochemical parameters like
BUN, plasma creatinine and plasma albumin. The BUN level
in CP treated rats increased signiﬁcantly to reach 85 ± 11.7 mg/
dl (21 ± 0.79 mg/dl in control rats). Plasma creatinine level was
also increased signiﬁcantly to reach 2.18 ± 0.24 mg/dl
(0.68 ± 0.04 mg/dl in control rats) after CP treatment. Simi-
larly, plasma albumin level decreased signiﬁcantly to reach
3.27 ± 0.09 g/dl (3.67 ± 0.03 g/dl in control rats). Co-treatment
of tannic acid with CP further increases the nephrotoxicity as
assessed by signiﬁcant increase in BUN to reach 124 ± 12 mg/
dl (85 ± 11.7 mg/dl in CP treated rats), plasma creatinine to
reach 4.35 ± 0.21 mg/dl (2.18 ± 0.24 mg/dl in CP treated rats)nnic acid along with cisplatin. Transverse section of normal control rat
id (E) and (F) and post-treatment of tannic acid (G) and (H). Sections
ved under magniﬁcation of 40· and 100· as described in Section 2. ﬁ
2030 K. Tikoo et al. / FEBS Letters 581 (2007) 2027–2035and decrease plasma albumin level 3.08 ± 0.13 g/dl (3.27 ±
0.09 g/dl in CP treated rats). In contrast to co-treatment of tan-
nic acid, post-treatment of tannic acid signiﬁcantly decreases
the nephrotoxicity in the CP treated rats. The BUN and plas-
ma creatinine level in tannic acid post treated rats decreased
signiﬁcantly from 85 ± 11.7 to 40 ± 4.18 mg/dl and 2.18 ±
0.24 to 1.25 ± 0.15 mg/dl, respectively (Table 1).
3.3. Eﬀect of co-treatment of tannic acid with reduced dose of
cisplatin (comparative nephrotoxicity)
Co-treatment of tannic acid with CP increases the nephro-
toxicity of cisplatin. Comparative nephrotoxicity study was
planned to ﬁnd out whether tannic acid co-treatment with re-
duced dose of CP (1.5 mg/kg) leads to a similar nephrotoxicity
proﬁle as with the routinely used dose of CP (5 mg/kg). Table 2
shows that co-treatment of tannic acid with CP (1.5 mg/kg)
developed almost equivalent polyuric acute renal failure as in p-p38
p38 
0
30
60
90
120
150
180
210
a b c d
p-
p3
8
%
 o
f c
o
n
tr
o
l **a
***b
***b
PARP
Actin
0
80
160
240
320
400
480
a b c d
PA
R
P
%
 o
f C
o
n
tr
o
l
*a
*b
***b
116 kDa
85 kDa
66 kDa
B
A
Fig. 2. Eﬀect of tannic acid co-treatment and post-treatment on PARP
cleavage and phosphorylation of p38 in cisplatin treated kidney. (A)
Western blot of PARP and (B) phosphorylation of p38. Lane a, total
cellular proteins of kidney of control animal; lane b, total cellular
proteins of kidney of cisplatin treated animal; lane c, total cellular
proteins of kidney of tannic acid co treated animal and lane d, total
cellular proteins of kidney of tannic acid post treated animal. Anti
actin and anti p38 antibody was used as loading control. Results were
normalized with respect to actin and p38 band intensities in respective
controls. Similar results were obtained in three independent set of
experiments. ***P < 0.001, **P < 0.01 and *P < 0.05 a vs control, b vs
cisplatin.CP (5 mg/kg) treated rats. There is signiﬁcant increase in
BUN levels 62 ± 11 mg/dl (21 ± 0.79 mg/dl in control rats)
and plasma creatinine levels 1.38 ± 0.05 mg/dl (0.68 ±
0.04 mg/dl in control rats).
3.4. Cisplatin induces histopathological changes in rat kidney
In the histopathology of kidney, while the normal control
group displays normal kidney histology (Fig. 1A and B),
extensive tubular epithelial cellular necrosis, desquamation,
vacuolization and swelling were observed in the CP treated
kidneys (Fig. 1C and D). Co-treatment of tannic acid with cis-
platin increases the tubular cell damage (Fig. 1E and F). How-
ever, post-treatment of tannic acid resulted in remarkable
improvement in the histological appearance and reduction in
tubular cell damage (Fig. 1G and H).
3.5. Cisplatin induces PARP cleavage and phosphorylation of
p38
Several reports suggest the role of PARP and phosphoryla-
tion of p38 in cisplatin induced nephrotoxicity [23,34]. We
studied the PARP cleavage and phosphorylation of p38 in
the kidney of the cisplatin treated rats. Fig. 2A, lane b shows
that after cisplatin treatment there is signiﬁcant increase in
PARP cleavage as compared to control group (Fig. 2A, lane
a) and it increases further by co-treatment of tannic acid
(Fig. 2A, lane c). However, there is a decrease in PARP cleav-
age by the post-treatment of tannic acid (Fig. 2A, lane d). Sug-
gesting that PARP activation is more pronounced in the
co-treatment group as compared to the CP treated group.
Compared to control animals phosphorylation of p38 is found
to be increased by cisplatin treatment (Fig. 2B, lanes a and b)
and it is further increased by co-treatment (Fig. 2B, lane c).
But there is signiﬁcant decrease in phosphorylation of p38 by
the post-treatment of tannic acid (Fig. 2B, lane d) as compared
to CP treated rats. Suggesting that kidney cells are undergoing
apoptotic cell death and co-treatment of tannic acid potenti-       Ac-H4
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Fig. 3. Eﬀect of tannic acid co-treatment and post-treatment in
cisplatin treated rat kidney on histone H4 acetylation. Lane a, acid
soluble nuclear proteins of control animal: lane b, acid soluble nuclear
proteins of cisplatin treated animal: lane c, acid soluble nuclear
proteins of tannic acid co treated animal and lane d, acid soluble
nuclear proteins of tannic acid post treated animal. Anti H4 antibody
was used as a loading controls. Results were normalized with respect to
H4 band intensities in respective controls. Similar results were
obtained in three independent set of experiments. ***P < 0.001 and
*P < 0.05 a vs control, b vs cisplatin.
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by decreasing PARP cleavage and phosphorylation of p38.
3.6. Hypoacetylation of histone H4 in cisplatin induced
nephrotoxicity
CP is known to cause histone H3 phosphorylation and
hyperacetylation of histone H4 in cancer cells in vitro [35].Fig. 4. Mass spectra of plasma proteins showing changes in plasma protein b
mass spectra of plasma protein (10 lg) digested with trypsin. Plasma samples
administered along with cisplatin (D). Blood was taken out after 15 min of tre
(100 ng) and subjected to MALDI TOF analyses as described in Section 2.We studied the changes in level of acetylation of histone H4
in the kidney of the cisplatin treated rats. As compared to con-
trol rat kidney, CP treatment decreases acetylation of histone
H4 (Fig. 3, lanes a and b). In case of co-treatment of tannic
acid there is further decrease in acetylation of H4 as compared
to CP treated rats (Fig. 3, lane c). However, in contrast to co-
treatment, post-treatment of tannic acid prevents decrease ininding by co-treatment of tannic acid on cisplatin treated rats. MALDI
of control (A) cisplatin treated (B) tannic acid (C) and tannic acid co
atment; plasma was separated from blood, digested by modiﬁed trypsin
Similar results were obtained in three independent set of experiments.
2032 K. Tikoo et al. / FEBS Letters 581 (2007) 2027–2035the acetylation of histone H4 in CP treated rats (Fig. 3, lane d).
Our data and other reports suggest that CP induces diﬀerent
histone modiﬁcations in diﬀerent cell types.
3.7. MALDI plasma protein proﬁling
Potentiation of nephrotoxicity by co-treatment of tannic
acid and comparative nephrotoxicity studies suggested us to
check the bioavailability of CP after tannic acid co-treatment.
We applied mass spectroscopic approach which provides indi-
rect evidence regarding CP/tannic acid and plasma proteinFig. 4 (contbinding. Plasma protein spectra were taken after diﬀerent
treatments. In each spectrum, 200–300 peaks were observed,
ion signals having suﬃcient S/N ratios were considered useful
in further analyses (Fig. 4).
In comparison to tryptic digested plasma of control animals
major peptide peaks (e.g. peptides having m/z 1266, 1299,
1440, 1455 and 1479) were suppressed after cisplatin treatment
in plasma taken after 15 min of drug injection (Fig. 4B). Tan-
nic acid treatment also suppresses same peaks which are sup-
pressed by CP and were present in control samples (Fig. 4C).inued)
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Fig. 5. Peak intensity obtained from mass spectra of plasma protein
(10 lg) digested with modiﬁed trypsin (100 ng). Peak intensities ratios
of treated to control samples were calculated by averaging the peak
intensities followed by t-tests of the intensity of the peak. (A)
Comparative change in peak intensity of albumin peptide identiﬁed
by MSMS spectra and having mass (m/z) 1479 after 15 min of drug
treatment. (B) Bar diagram of peak intensity ratio of peptide mass (m/
z) 1479 after 15 min of drug treatment. Results are expressed as
means ± S.E.M. of three independent experiments performed in
triplicates, ***P < 0.001 a vs control.
K. Tikoo et al. / FEBS Letters 581 (2007) 2027–2035 2033Furthermore, co-treatment of tannic acid with CP resulted in
further suppression of these peaks in the mass spectra of tryp-
tic digested plasma proteins (Fig. 4D). These results indicate
the involvement of competitive binding between CP and tannic
acid to form cisplatin–protein or tannic acid–protein adducts.
The possibility of same binding site for CP and tannic acid is
indicated by the suppression of same peaks e.g. major peptide
peak of mass 1479 by CP as well as tannic acid (Fig 5A and B).4. Discussion
Present study was conceived to study the eﬀect of tannic acid
on CP induced nephrotoxicity. Here, we provide evidence that
co-treatment of tannic acid with CP increases the nephrotoxi-
city while the post-treatment prevents it up to certain extent.
Nephrotoxic damage by cisplatin shows increase in BUN
and creatinine levels. Comparative nephrotoxicity proﬁling
suggests that tannic acid increases the CP induced nephrotox-
icity. The elevated levels of BUN and creatinine suggest an in-
crease in the toxicity of cisplatin in the presence of tannic acid
and this potentiating eﬀect of tannic acid can be observed at
both therapeutic as well as sub therapeutic dose levels. More-
over, histopathology examination of kidney sections also sup-
ports our biochemical data. These results indicate the central
role of tannic acid in potentiating the nephrotoxic eﬀect of
CP and point towards its profound clinical implications. It
can be argued that tannic acid also shows a protective eﬀectowing to its antioxidant action but the fact that this polyphe-
nol exerts a modulatory eﬀect depending upon the time of
administration.
CP induced apoptosis involves PARP cleavage, caspase-3
and bcl-2 in renal epithelial cells [36]. We observed a signiﬁcant
increase in PARP cleavage in CP treated rat kidneys, indicat-
ing cells are undergoing apoptotic cell death. Co-treatment of
tannic acid resulted in further increase in PARP cleavage while
post-treatment prevents its cleavage. Decrease in cleavage of
PARP in post-treatment group might be due to the inhibition
of PARG by tannic acid, which is a known PARG inhibitor
[29,30]. Tannic acid inhibits PARG thereby instigating a neg-
ative feedback inhibition loop leading to inactivation along
with a decrease in expression of PARP.
Oxidants are potent activators of mitogen activated protein
kinases (MAPKs), including p38 MAPK [37–39]. CP stimu-
lates the production of ROS, including hydroxyl radicals.
The formation of hydroxyl radicals in CP treated kidney cells,
both in vitro and in vivo, involves the release of iron from the
heme groups of cytochrome P-450 2E1 [10]. As far as down-
stream signaling is concerned, CP reportedly causes activation
of all three MAPKs in kidney both in vitro and in vivo [34].
However the role of p38 MAPK inhibition in CP induced
nephrotoxicity has recently been demonstrated [40]. We also
observed similar results, as phosphorylation of p38 is increased
in cisplatin treated rats. Increase in the MAPK activation is
thought to play a central role in mediation of CP induced
nephrotoxic damage as it has been shown that pharmacologi-
cal inhibition of p38 MAPK results in decreased nephrotoxi-
city in vivo [40]. Co-treatment of tannic acid along with CP
resulted in further increase in phosphorylation of p38, where
as post-treatment of tannic acid resulted in a decrease in phos-
phorylation of p38. Suggesting that it is the time of tannic acid
treatment (co- or post-treatment) which decides whether to
potentiate or to prevent CP induced nephrotoxicity. Down-
stream target of PARP or MAPK signaling is chromatin so
we studied the role of chromatin dynamics in transducing
the upstream signals. We therefore investigated change in acet-
ylation of histone H4 in CP induced nephrotoxicity. CP in-
duces phosphorylation of histone H3 and hyperacetylation of
Histone H4 in cancer cells [35]. However, CP induces hypo-
acetylation of histone H4 in rat kidney. Co-treatment with tan-
nic acid further reduces the acetylation of histone H4, where as
post-treatment results in reverting acetylation to control level.
It is widely believed that acetylation status of histones corre-
lates well with the transcriptional activation of genes [41];
hyperacetylation signiﬁes a transcriptionaly active state while
hypoacetylation leads to a transcriptionally repressed state.
These ﬁndings substantiate the pivotal role played by chroma-
tin dynamics in mediating toxic responses. Although, this pro-
cess could occur by MAPK dependent or by independent
recruitment of deacetylating enzymes which leads to chromatin
condensation and transcriptional repression but our data def-
initely suggests that global change in histone acetylation may
serve as predictive markers for drug toxicity and eﬃcacy which
is of fundamental importance in determining the eﬀectiveness
of anticancer drugs.
Tannic acid per se does not cause any nephrotoxicity at the
doses used for this study and cisplatin is not reported to inter-
act with this polyphenol. Tannins are known to bind cova-
lently with proteins [42]. The strongest interactions among
tannins are found between BSA and tannic acid [42]. CP is also
2034 K. Tikoo et al. / FEBS Letters 581 (2007) 2027–2035reported to bind with proteins in an irreversible manner
[43,44].
Our data suggest that the both tannic acid as well as cisplatin
bind to albumin in plasma and share similar binding sites. CP
is also known to form DNA adduct but out of 10 molecules
only one enters the nucleus and rest nine bind to proteins
[45]. It is already reported that tannic acid lends a conspicuous
change in the conformation of BSA in vitro [42]. Moreover, by
translating the MS–MS spectra to amino acid sequence by
MASCOT search, we found that the most predominant peak
1479 corresponds to that of albumin (data not shown). Similar
in vitro studies with BSA, tannic acid and cisplatin also showed
results identical to what we found in tryptic digest of plasma
samples (data not shown). Suppression of same peptide peaks
by cisplatin and tannic acid treatment provides indirect evi-
dence that tannic acid increases the bioavailability of cisplatin
which may be responsible for increased nephrotoxicity.
These ﬁndings substantiate the need of further studies to
delineate the roles of polyphenols in general and tannic acid
in particular in diﬀerent cancer models. These studies will aid
in the development of a novel therapeutic dose design which
is a fulcral aspect of cancer research.
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